Last 18 quarters of trend data · Healthcare · Vaccines & Infectious Disease
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.49 | 23.65 | 21.86 | 31.15 | 74.89 | 22.57 | 20.48 | 18.66 | 13.36 | 12.16 | 5.78 | 5.51 | 13.82 | 54.14 | 31.86 | — | — | — | — |
| — | +4.8% | +6.7% | +67.0% | +460.4% | +85.6% | +254.6% | +238.6% | -3.3% | -77.5% | -81.9% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.13 | 0.52 | 0.44 | 0.77 | 1.60 | 0.79 | 0.44 | 0.56 | 0.53 | 0.57 | — | 6.95 | 10.00 | 10.19 | 3.36 | — | — | — | — |
| — | -34.1% | -0.4% | +37.3% | +201.4% | +37.5% | — | -91.9% | -94.7% | -94.4% | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.9% | 64.3% | 42.7% | 50.3% | 60.4% | 53.5% | 56.8% | 76.1% | 62.0% | 42.8% | 68.8% | 58.3% | 59.0% | 61.7% | 56.8% | 54.3% | — | — | — |
| — | +20.2% | -24.7% | -33.9% | -2.5% | +25.1% | -17.5% | +30.4% | +5.1% | -30.7% | +21.2% | +7.5% | — | — | — | — | — | — | — | |
| Operating Margin | -4200.5% | -1502.5% | -4606.8% | -1579.5% | -8953.5% | -3134.0% | -4440.0% | -1594.3% | -1318.2% | -1329.1% | -1105.9% | -1050.9% | -733.8% | -1623.0% | -2540.8% | -7516.0% | — | — | — |
| — | +52.1% | -3.8% | +0.9% | -579.2% | -135.8% | -301.5% | -51.7% | -79.6% | +18.1% | +56.5% | +86.0% | — | — | — | — | — | — | — | |
| Net Margin | -4526.9% | -1909.1% | -5014.6% | -2935.6% | -9042.8% | -3221.6% | -4427.4% | -1850.9% | -1498.9% | -1465.4% | -1105.9% | -1050.9% | -733.8% | -1617.2% | -2542.5% | -7536.1% | — | — | — |
| — | +40.7% | -13.3% | -58.6% | -503.3% | -119.8% | -300.4% | -76.1% | -104.3% | +9.4% | +56.5% | +86.1% | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -141.7% | -10.1% | -23.7% | -17.9% | -43.6% | -27.4% | -28.3% | -14.3% | -14.7% | -37.2% | — | -241.2% | -82.6% | -67.0% | -115.5% | -93.7% | -290.3% | — | — |
| — | +63.2% | +16.1% | -25.7% | -196.6% | +26.2% | — | +94.1% | +82.2% | +44.5% | — | -157.4% | +71.6% | — | — | — | — | — | — | |
| ROA | -131.2% | -9.2% | -22.3% | -17.0% | -40.8% | -25.4% | -26.1% | -12.9% | -13.3% | -30.8% | -350.2% | -194.1% | -73.5% | -61.6% | -100.1% | -70.3% | -217.6% | -37959.1% | — |
| — | +63.9% | +14.5% | -31.5% | -206.2% | +17.4% | +92.6% | +93.3% | +81.9% | +50.1% | -250.0% | -176.2% | +66.2% | +99.8% | — | — | — | — | — | |
| ROIC | -102.2% | -5.9% | -17.0% | -7.6% | -32.2% | -19.8% | -21.2% | -9.1% | -9.7% | -25.3% | — | -904.4% | -569.0% | -685.5% | -670.1% | -311.4% | -10204.0% | — | — |
| — | +70.1% | +19.9% | +16.3% | -232.3% | +21.9% | — | +99.0% | +98.3% | +96.3% | — | -190.4% | +94.4% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 | 0.03 | 0.00 | 0.02 | 0.02 | 0.02 | — | 0.17 | 0.11 | 0.05 | 0.07 | 0.57 | 0.11 | — | — |
| — | -21.0% | +826.1% | +31.4% | -64.5% | +58.9% | — | -90.7% | -81.0% | -60.7% | — | -71.1% | -2.2% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.74 | 0.18 | 0.29 | 1.74 | 0.74 | 0.07 | 0.12 | 0.05 | 0.07 | 0.38 | 0.07 | 3.88 | 8.44 | 15.39 | 20.91 | 2.67 | 9.95 | 0.01 | — |
| — | +138.5% | +145.1% | +3176.5% | +894.5% | -80.4% | +58.6% | -98.6% | -99.1% | -97.6% | -99.6% | +45.5% | -15.2% | +246683.9% | — | — | — | — | — | |
| Quick Ratio | 1.74 | 0.18 | 0.29 | 1.74 | 0.74 | 0.07 | 0.12 | 0.05 | 0.07 | 0.37 | 0.06 | 3.79 | 8.30 | 15.27 | 20.91 | 2.67 | 9.95 | 0.01 | — |
| — | +138.5% | +145.1% | +3176.5% | +1039.1% | -79.8% | +89.0% | -98.6% | -99.2% | -97.6% | -99.7% | +42.2% | -16.6% | +244766.5% | — | — | — | — | — | |
| Interest Coverage | -198.43 | -3.69 | -12.29 | -139.84 | -99.45 | -248.58 | — | -5.32 | -7.28 | -9.74 | — | -346.45 | — | — | -1094.91 | -373.25 | -320.98 | -207.14 | -21.05 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 18 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MGRX stock.
Mangoceuticals, Inc.'s current P/E is -0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Mangoceuticals, Inc.'s current operating margin is -4200.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Mangoceuticals, Inc.'s business trajectory between earnings reports.